Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 2/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | BUB1 | O43683 | 3/20 | 0.36 |
| ▸ | MET | P08581 | 1/20 | 0.35 |
| ▸ | TTBK1 | Q5TCY1 | 2/20 | 0.35 |
| ▸ | TTBK2 | Q6IQ55 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL174728 | 0.86 | MEN1 (0.39) | MEN1KMT2AABCB1AURKAAURKB | |
| SCHEMBL174693 | 0.69 | MEN1 (0.38) | MEN1KMT2ASMN1; SMN2POLBMET | |
| SCHEMBL173973 | 0.68 | AURKA (0.59) | AURKAAURKBGSK3B | |
| SCHEMBL175002 | 0.66 | GSK3B (0.48) | AURKAGSK3BTTBK1TTBK2 | |
| SCHEMBL162870 | 0.65 | TRPA1 (0.40) | MEN1KMT2ATTBK1TTBK2 | |
| SCHEMBL1197498 | 0.64 | LMNA (0.68) | MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL27966694 | 0.62 | PTGIR (0.46) | MEN1KMT2ASMN1; SMN2MET | |
| SCHEMBL166205 | 0.62 | TRPA1 (0.38) | MEN1KMT2ATTBK1TTBK2 | |
| SCHEMBL173737 | 0.62 | POLB (0.69) | MEN1KMT2ASMN1; SMN2POLB | |
| SCHEMBL31511072 | 0.62 | SMN1; SMN2 (0.47) | MEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130303533-A1 | AZOLOPYRIDINE AND AZOLOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2013-11-14 | — | — | US | disclosed |
| EP-2611809-A1 | AZOLOPYRIDINE AND AZOLOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012030924-A1 | AZOLOPYRIDINE AND AZOLOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303533-A1 | AZOLOPYRIDINE AND AZOLOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | JAK3, JAK2, JAK1 | MEN1 2341/4885KMT2A 610/4885SMN1; SMN2 3140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.